All In Biotech

Drug Trial Radar · NCT07235384

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

A Phase 1/1b Randomized, Double Blind, Placebo-controlled, Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis (AD)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Dec 28, 2027

Study completion Dec 28, 2027

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • ZL-1503Drug

    Healthy volunteers will receive ZL-1503.

  • PlaceboDrug

    Healthy volunteers will receive placebo.

  • ZL-1503Drug

    Participants with moderate to severe atopic dermatitis will receive ZL-1503.

  • PlaceboDrug

    Participants with moderate to severe atopic dermatitis will receive placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 48 weeks after last intervention
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 48 weeks after last intervention
  3. Number of participants with clinical laboratory abnormalitiesTime frame: Up to 48 weeks after last intervention
  4. Number of participants with vital sign abnormalitiesTime frame: Up to 48 weeks after last intervention
  5. Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: Up to 48 weeks after last intervention

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Veracity Clinical Research

    Woolloongabba, Queensland, Australia · Recruiting

  • Skin Health Institute

    Carlton, Victoria, Australia · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Dermatology Hospital of Jiangxi Province

    Nanchang, Jiangxi, China · Recruiting

  • Shandong Provincial Dermatology Hospital

    Jinan, Shandong, China · Recruiting

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Aotearoa Clinical Trials

    Auckland, Auckland, New Zealand · Recruiting

  • Momentum Auckland

    Takapuna, Auckland, New Zealand · Recruiting

  • Momentum Hamilton

    Hamilton, Hamilton, New Zealand · Recruiting

  • Momentum Palmerston North

    Palmerston North, Mananwatu, New Zealand · Recruiting

  • Momentum Hutt Valley

    Upper Hutt, Wellington Region, New Zealand · Recruiting

  • Momentum Kapiti

    Waikanae, Wellington Region, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.